Huabin Li

Dr. Huabin Li


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SWSihua Wang
Sihua Wang
YZYuan Zhang
Yuan Zhang
YWYan Wang
Yan Wang
PYPing Ye
Ping Ye
JLJun Li
Jun Li
JXJiahong Xia
Jiahong Xia
Previous studies mainly focused on the role of the epidermal growth factor receptor (EGFR) in tumor cells, whereas the effects of the EGFR on immune responses has not been determined. Our study shows that the EGFR signaling pathway play a role in the regulation of regulatory T cells (Treg cells) in cancer patients. The EGF-like growth factor Amphiregulin (AREG) protein was frequently up-regulated in a tissue microarray, which was associated with worse overall survival. Additionally, in sera, tissue specimens, and effusions of lung or gastric cancer patients, up-regulated AREG protein enhanced the suppressive function of Treg cells. AREG maintained the Treg cell suppressive function via the EGFR/GSK-3β/Foxp3 axis in vitro and in vivo. Furthermore, inhibition of EGFR by the tyrosine kinase inhibitor gefitinib restored the activity of GSK-3β and attenuated Treg cell function. β-TrCP was involved in GSK-3β-mediated Foxp3 degradation, and mass spectrometry identified Lys356 as the ubiquitination site of Foxp3 by β-TrCP. These findings demonstrate the posttranslational regulation of Foxp3 expression by AREG in cancer patients through AREG/EGFR/GSK-3β signaling, which could lead to Foxp3 protein degradation in Treg cells and a potential therapeutic target for cancer treatment.

21 November 2022 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
Chengshuo WangChengshuo Wang
Chengshuo Wang
YBYixiao Bao
Yixiao Bao
JCJianjun Chen
Jianjun Chen
XCXiaoyang Chen
Xiaoyang Chen
LClei Cheng
lei Cheng
C(Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G)
Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G)
Wang C, et al. Allergy Asthma Immunol Res. 2022 Nov;14(6):604-652. https://doi.org/10.4168/aair.2022.14.6.604

1 July 2016 in Immunity
Verified
Journal Article
Closed access
HYHuang-Yu Yang
Huang-Yu Yang
JBJoseph Barbi
Joseph Barbi
CWChao-Yi Wu
Chao-Yi Wu
YZYing Zheng
Ying Zheng
PVPaolo D.A. Vignali
Paolo D.A. Vignali
FPFan Pan
Fan Pan

1 January 2009 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
ZMZhonglin Mou
Zhonglin Mou
JXJiahong Xia
Jiahong Xia
YTYenong Tan
Yenong Tan
XWXiangdong Wang
Xiangdong Wang
YZYuan Zhang
Yuan Zhang
DHDemin Han
Demin Han
Conclusion. Thymic stromal lymphopoietin (TSLP) played an important role in the pathogenesis of allergic rhinitis (AR) and can be regarded a potential therapeutic target for the management of AR. Objective. To evaluate the possible role of TSLP in the pathogenesis of AR. Patients and methods. We enrolled 16 patients of AR to investigate the expression of TSLP in nasal mucosa and evaluate the link of TSLP and interleukin-4 (IL-4). Expression of TSLP was detected by immunohistochemical analysis and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), and concentrations of TSLP and IL-4 were measured by enzyme-linked immunosorbent assay (ELISA). Results. TSLP was detected in all samples and the mRNA and protein expression of TSLP is increased significantly in AR nasal mucosa compared with normal control (P<0.05). TSLP production is tightly correlated with IL-4 and severity of AR (P<0.05).

1 January 2020 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
ZLZheng Liu
Zheng Liu
JCJianjun Chen
Jianjun Chen
LClei Cheng
lei Cheng
HLHuabin Li
Huabin Li
SLShixi Liu
Shixi Liu
LZLuo Zhang
Luo Zhang
The current document is based on a consensus reached by a panel of experts from the Chinese Society of Allergy and the Chinese Society of Otorhinolaryngology-Head and Neck Surgery, Rhinology Group. Chronic rhinosinusitis (CRS) affects approximately 8% of Chinese adults. The inflammatory and remodeling mechanisms of CRS in the Chinese population differ from those observed in the populations of European descent. Recently, precision medicine has been used to treat inflammation by targeting key biomarkers that are involved in the process. However, there are no CRS guidelines or a consensus available from China that can be shared with the international academia. The guidelines presented in this paper cover the epidemiology, economic burden, genetics and epigenetics, mechanisms, phenotypes and endotypes, diagnosis and differential diagnosis, management, and the current status of CRS in China. These guidelines-with a focus on China-will improve the abilities of clinical and medical staff during the treatment of CRS. Additionally, they will help international agencies in improving the verification of CRS endotypes, mapping of eosinophilic shifts, the identification of suitable biomarkers for endotyping, and predicting responses to therapies. In conclusion, these guidelines will help select therapies, such as pharmacotherapy, surgical approaches and innovative biotherapeutics, which are tailored to each of the individual CRS endotypes.

7 November 2016 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
SFShaoyan Feng
Shaoyan Feng
ZLZibin Liang
Zibin Liang
RZRongkai Zhang
Rongkai Zhang
WLWei Liao
Wei Liao
YCYuan Chen
Yuan Chen
HLHuabin Li
Huabin Li